JP7791102B2 - アルファ１－アンチトリプシンのモジュレーター - Google Patents

アルファ１－アンチトリプシンのモジュレーター

Info

Publication number
JP7791102B2
JP7791102B2 JP2022559583A JP2022559583A JP7791102B2 JP 7791102 B2 JP7791102 B2 JP 7791102B2 JP 2022559583 A JP2022559583 A JP 2022559583A JP 2022559583 A JP2022559583 A JP 2022559583A JP 7791102 B2 JP7791102 B2 JP 7791102B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
compound
mmol
compounds
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559583A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023520397A5 (cg-RX-API-DMAC10.html
JP2023520397A (ja
Inventor
サイモン ジルー，
マイケル フィリップ クラーク，
マイケル アーロン ブロドニー，
ピーター ジョーンズ，
マイケル ポール デニンノ，
ウェンシン グ，
チン タン，
スティーブン デイビッド ストーン，
ティモシー ジェイ． センター，
ザッカリー ゲイル－デイ，
ダイアン マリー バウチャー，
レブ ティー．ディー． ファニング，
エイミー ビー． ホール，
デニス ジェイムズ ハーレー，
マック アーサー ジュニア ジョンソン，
ジョン パトリック マクスウェル，
レベッカ ジェーン スウェット，
ティモシー ルイス タプレイ，
スティーブン エー． トムソン，
ヴェロニク ダマグネス，
ケヴィン マイケル コットレル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2023520397A publication Critical patent/JP2023520397A/ja
Publication of JP2023520397A5 publication Critical patent/JP2023520397A5/ja
Application granted granted Critical
Publication of JP7791102B2 publication Critical patent/JP7791102B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022559583A 2020-04-03 2021-04-02 アルファ１－アンチトリプシンのモジュレーター Active JP7791102B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063004683P 2020-04-03 2020-04-03
US63/004,683 2020-04-03
PCT/US2021/025623 WO2021203028A1 (en) 2020-04-03 2021-04-02 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)

Publications (3)

Publication Number Publication Date
JP2023520397A JP2023520397A (ja) 2023-05-17
JP2023520397A5 JP2023520397A5 (cg-RX-API-DMAC10.html) 2024-04-10
JP7791102B2 true JP7791102B2 (ja) 2025-12-23

Family

ID=75674976

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022559583A Active JP7791102B2 (ja) 2020-04-03 2021-04-02 アルファ１－アンチトリプシンのモジュレーター

Country Status (7)

Country Link
US (1) US12662471B2 (cg-RX-API-DMAC10.html)
EP (1) EP4126819A1 (cg-RX-API-DMAC10.html)
JP (1) JP7791102B2 (cg-RX-API-DMAC10.html)
CN (1) CN115697969B (cg-RX-API-DMAC10.html)
AU (1) AU2021246527A1 (cg-RX-API-DMAC10.html)
CA (1) CA3179189A1 (cg-RX-API-DMAC10.html)
WO (1) WO2021203028A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210060A1 (ar) 2018-10-05 2023-01-30 Vertex Pharma معدلات لمضاد تريبسين ألفا-1
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
CN115697969B (zh) 2020-04-03 2026-08-11 弗特克斯药品有限公司 α-1抗胰蛋白酶调节剂
AU2021247285A1 (en) 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
EP4188931A2 (en) 2020-07-27 2023-06-07 Vertex Pharmaceuticals Incorporated Processes for preparing modulators of alpha-1 antitrypsin
WO2022104353A1 (en) 2020-11-12 2022-05-19 Vertex Pharmaceuticals Incorporated Methods of monitoring alpha-1 antitrypsin (aat) deficiency by measuring polymerised aat
WO2026136445A1 (en) 2024-12-17 2026-06-25 Sub21, Inc. A1at modulators

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000072751A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd イソキノリノン誘導体
JP2000281654A (ja) 1999-03-26 2000-10-10 Tanabe Seiyaku Co Ltd イソキノリン誘導体
WO2009060209A1 (en) 2007-11-09 2009-05-14 Argenta Discovery Limited 6,6-fused bicyclic aromatic compounds and their therapeuti use
US20100016285A1 (en) 2007-01-24 2010-01-21 Mochida Pharmaceutical Co., Ltd. Heterocyclidene-n-(aryl) acetamide derivative
WO2019243841A1 (en) 2018-06-22 2019-12-26 Ucl Business Ltd Novel compounds

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2612503A (en) * 1949-04-19 1952-09-30 Smith Kline French Lab Basic ether-substituted isoquinolines
US2538341A (en) * 1949-09-20 1951-01-16 Smith Kline French Lab Method for producing 1-hydroxyisoquinolines
US3404157A (en) 1965-02-24 1968-10-01 American Cyanamid Co Substituted pyrroloindazole compounds
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
US4198415A (en) 1979-01-22 1980-04-15 Eli Lilly And Company Prolactin inhibiting octahydro pyrazolo[3,4-g]quinolines
US4647667A (en) 1982-11-03 1987-03-03 Eli Lilly And Company Octa- and deca-hydroquinoline intermediates
US4778894A (en) 1983-09-26 1988-10-18 Eli Lilly And Company 6 oxo-decahydroquinolines
US5358949A (en) * 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
DK158590D0 (da) 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
US6201129B1 (en) 1995-02-01 2001-03-13 Univ. College Cardiff Consultants Tricyclic derivatives and their use as anti-cancer agents
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
GB9827882D0 (en) 1998-12-17 1999-02-10 Smithkline Beecham Plc Novel compounds
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
FR2802532A1 (fr) 1999-12-17 2001-06-22 Sanofi Synthelabo Derives de 2-phenyl-quinoleine, leur preparation et leur application en therapeutique
BR0016878A (pt) 1999-12-29 2002-10-08 Wyeth Corp Inibidores tricìclicos de cinases protéicas
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
CN1452619A (zh) * 2000-07-26 2003-10-29 史密斯克莱·比奇曼公司 具有抗细菌活性的氨基哌啶喹啉和它们的氮杂等排的类似物
IL154981A0 (en) 2000-10-10 2003-10-31 Smithkline Beecham Corp Substituted indoles, pharmaceutical compositions containing such indoles and their use as ppay-y-binding agents
US6906192B2 (en) 2000-11-07 2005-06-14 Bristol Myers Squibb Company Processes for the preparation of acid derivatives useful as serine protease inhibitors
US20030212085A1 (en) 2001-04-17 2003-11-13 Mccall Robert B. Treatment of fibromyalgia and chronic fatigue syndrome
US20040176361A1 (en) 2001-05-23 2004-09-09 Masakazu Fujio Fused heterocyclic compound and medicinal use thereof
US6706423B2 (en) 2001-12-27 2004-03-16 Lightronik Technology Inc. Organic EL device
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2004108120A1 (en) 2003-06-11 2004-12-16 Pfizer Products Inc. Use of growth hormone secretagogues for treatment of fibromyalgia
JP2006528661A (ja) 2003-07-25 2006-12-21 ファイザー・インク アミノピラゾール化合物およびｃｈｋ１阻害剤としての使用
US7208601B2 (en) 2003-08-08 2007-04-24 Mjalli Adnan M M Aryl and heteroaryl compounds, compositions, and methods of use
US7723352B2 (en) * 2003-09-23 2010-05-25 Merck Sharp & Dohme Isoquinolinone potassium channel inhibitors
EA200700243A1 (ru) 2004-07-14 2007-08-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способы лечения гепатита с
US20070203209A1 (en) 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
US8097644B2 (en) 2006-03-28 2012-01-17 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (S1P) receptor antagonist
AU2007234408B2 (en) 2006-04-04 2011-05-19 Fibrogen, Inc. Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
JP5421767B2 (ja) * 2006-04-10 2014-02-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション ヒト胚性幹細胞を使用して薬学的化合物および他の化学物質の毒性を評価するための試薬および方法
TW200813054A (en) 2006-06-02 2008-03-16 Elan Pharm Inc Fused, tricyclic sulfonamide inhibitors of gamma secretase
WO2008019357A2 (en) 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
WO2008143633A2 (en) 2007-01-10 2008-11-27 University Of Florida Compounds and methods for treatment of alpha-1 antitrypsin deficiency
JP5107589B2 (ja) 2007-02-13 2012-12-26 旭化成株式会社 インドール誘導体
RU2337915C1 (ru) * 2007-03-14 2008-11-10 Общество с ограниченной ответственностью "Инжиниринговая компания "ИНКОМП-НЕФТЬ" Комплексонат нитрилотри(метиленфосфонато)-2-фенил-3-этил-8-оксихинолин натриевая соль в качестве ингибитора солеотложений
DE102008022521A1 (de) 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazin-2,5-dione und ihre Verwendung
RS54165B1 (sr) 2008-04-16 2015-12-31 Karo Bio Ab Novi ligandi za estrogenski receptor
WO2009158587A1 (en) 2008-06-26 2009-12-30 Inspire Pharmaceuticals, Inc. Method for treating pulmonary diseases using rho kinase inhibitor compounds
WO2011056222A1 (en) 2009-11-05 2011-05-12 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein aggregation
WO2011110852A1 (en) 2010-03-10 2011-09-15 Astrazeneca Ab Polymorphic forms of 6- [2- (4 -cyanophenyl) - 2h - pyrazol - 3 - yl] - 5 -methyl - 3 - oxo - 4 - (trifluoromethyl - phenyl) 3,4-dihydropyrazine-2-carboxylic acid ethylamide
CA3034600C (en) 2010-05-07 2020-11-10 Genentech, Inc. Pyridone and aza-pyridone compounds and methods of use
RU2589831C2 (ru) 2010-08-04 2016-07-10 Грюненталь Гмбх ЛЕКАРСТВЕННАЯ ДОЗИРОВАННАЯ ФОРМА, КОТОРАЯ СОДЕРЖИТ 6'-ФТОР-(N-МЕТИЛ- ИЛИ N, N-ДИМЕТИЛ-)-4-ФЕНИЛ-4', 9'-ДИГИДРО-3'Н-СПИРО[ЦИКЛОГЕКСАН-1, 1'-ПИРАНО[3, 4, b]ИНДОЛ]-4-АМИН
CN103140758B (zh) 2010-09-24 2015-03-11 基立福疗法公司 免疫层析装置、方法和试剂盒
JPWO2012063753A1 (ja) 2010-11-08 2014-05-12 日本電気株式会社 インドール系化合物、並びにこれを用いた光電変換用色素、半導体電極、光電変換素子および光電気化学電池
US9012773B2 (en) 2011-02-14 2015-04-21 Nec Corporation Thiazole-based compound and uses thereof
EP3628327A1 (en) 2011-06-24 2020-04-01 The Regents of the University of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
CN103239451A (zh) * 2012-02-10 2013-08-14 上海医学生命科学研究中心有限公司 吡咯并喹啉醌在治疗和/或预防肝纤维化中的应用
US20140135359A1 (en) 2012-11-12 2014-05-15 Louis C. Martineau Methods of designing, preparing, and using novel protonophores
AP2016008970A0 (en) 2013-07-10 2016-01-31 Bayer Pharma AG Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
US9572794B2 (en) 2014-08-06 2017-02-21 Vanderbilt University Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists
WO2016154051A1 (en) * 2015-03-20 2016-09-29 University Of Florida Research Foundation, Inc. Combination therapy for treating infections diseases
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
SG10202103844WA (en) 2015-12-30 2021-06-29 Genentech Inc Use of tryptophan derivatives for protein formulations
CN109414596B (zh) 2016-05-12 2023-09-29 密歇根大学董事会 Ash1l抑制剂和用其进行治疗的方法
HUE060119T2 (hu) 2016-05-31 2023-02-28 Spexis Ag Béta-hairpin peptidomimetikum elasztáz gátló hatással és annak aeroszolos adagolási formái
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
UY37581A (es) 2017-02-02 2018-08-31 Gilead Sciences Inc Compuestos para el tratamiento de la infección por virus de la hepatitis b
CN111163774A (zh) 2017-05-26 2020-05-15 罗格斯新泽西州立大学 细菌外排泵抑制剂
CN109111426B (zh) * 2017-06-23 2021-12-14 中国科学院上海药物研究所 一类稠合双环杂芳基或芳基化合物，及其用途
CN110546150B (zh) 2017-10-19 2021-12-21 江苏豪森药业集团有限公司 含吡唑基的三并环类衍生物、其制备方法和应用
JP7212693B2 (ja) * 2017-11-01 2023-01-25 ブリストル－マイヤーズ スクイブ カンパニー ファルネソイドｘ受容体モジュレーターとしての架橋二環化合物
CN107698505A (zh) 2017-11-20 2018-02-16 孙婷婷 一种诺得司他的制备方法
CR20200263A (es) * 2017-12-13 2020-07-26 Lupin Ltd Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5
CN111971278B (zh) 2018-01-31 2023-08-11 默克专利有限公司 用作irak抑制剂的喹啉化合物及其用途
TWI748194B (zh) 2018-06-28 2021-12-01 德商菲尼克斯 Ｆｘｒ有限責任公司 含有雙環核心部分之新穎lxr調節劑
CA3108388A1 (en) * 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3620164A1 (en) * 2018-09-05 2020-03-11 Genoscience Pharma SAS Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins b (ctsb), l (ctsl) and d (ctsd) related diseases
JOP20210060A1 (ar) 2018-10-05 2023-01-30 Vertex Pharma معدلات لمضاد تريبسين ألفا-1
CN110776459B (zh) 2019-03-19 2023-01-24 江苏知原药业股份有限公司 7-羟基-2-喹诺酮-二硫代氨基甲酸酯类胆碱酯酶抑制剂
US11884672B2 (en) 2019-05-14 2024-01-30 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
TW202116303A (zh) 2019-10-02 2021-05-01 美商維泰克斯製藥公司 α—１抗胰蛋白酶缺乏症之治療方法
KR20220133227A (ko) 2020-01-30 2022-10-04 버텍스 파마슈티칼스 인코포레이티드 알파-1 항트립신 결핍증의 치료 방법
CN115697969B (zh) 2020-04-03 2026-08-11 弗特克斯药品有限公司 α-1抗胰蛋白酶调节剂
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
CA3177531A1 (en) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Indole derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd)
WO2021203007A1 (en) 2020-04-03 2021-10-07 Vertex Pharmaceuticals Incorporated Substituted 5-hydroxyindole compounds as modulators of alpha-1 antitrypsin
AU2021247285A1 (en) 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
AU2021247282A1 (en) 2020-04-03 2022-10-27 Vertex Pharmaceuticals Incorporated Modulators of alpha-1 antitrypsin
EP4188931A2 (en) 2020-07-27 2023-06-07 Vertex Pharmaceuticals Incorporated Processes for preparing modulators of alpha-1 antitrypsin
WO2022104353A1 (en) 2020-11-12 2022-05-19 Vertex Pharmaceuticals Incorporated Methods of monitoring alpha-1 antitrypsin (aat) deficiency by measuring polymerised aat
US20240002386A1 (en) 2020-11-17 2024-01-04 Vertex Pharmaceuticals Incorporated Solid forms of 4-(5-(4-fluorophenyl)-6-(tetrahydro-2h-pyran-4-yl)-1,5-dihydropyrrolo[2,3-f]indazol-7-yl)benzoic acid
TW202421121A (zh) 2022-09-09 2024-06-01 美商維泰克斯製藥公司 α-１抗胰蛋白酶之調節劑

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000072751A (ja) 1998-08-26 2000-03-07 Tanabe Seiyaku Co Ltd イソキノリノン誘導体
JP2000281654A (ja) 1999-03-26 2000-10-10 Tanabe Seiyaku Co Ltd イソキノリン誘導体
US20100016285A1 (en) 2007-01-24 2010-01-21 Mochida Pharmaceutical Co., Ltd. Heterocyclidene-n-(aryl) acetamide derivative
WO2009060209A1 (en) 2007-11-09 2009-05-14 Argenta Discovery Limited 6,6-fused bicyclic aromatic compounds and their therapeuti use
WO2019243841A1 (en) 2018-06-22 2019-12-26 Ucl Business Ltd Novel compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAS REGISTRY No. 1880486-29-2等，DATABASE REGISTRY [online]，[検索日2025.01.16]，2016年，Retrieved from: STN
KATHURIA, A. et al.，"Substrate specificity of acetoxy derivatives of coumarins and quinolones towards Calreticulin mediated transacetylation: Investigations on antiplatelet function"，Bioorganic & Medicinal Chemistry，2012年，Vol. 20, No. 4，pp. 1624-1638，DOI: 10.1016/j.bmc.2011.11.016
KHUSNUTDINOV, R. et al.，"Quinoline Synthesis by the Reaction of Anilines with 1,2-diols Catalyzed by Iron Compounds"，Journal of Heterocyclic Chemistry，2015年，Vol. 53, No. 4，pp. 1022-1029，DOI: 10.1002/jhet.2425
MODI, A. R. et al.，"Synthesis of 7-hydroxy-3-alkylisoquinolones and 7-hydroxy-3-alkylisocoumarins from 4-hydroxyhomophthalic acid"，Indian Journal of Chemistry，1979年，Vol. 17B, No. 4，pp. 360-363
PRIYA, N. et al.，"Characterization of 4-methyl-2-oxo-1,2-dihydroquinolin-6-yl acetate as an effective antiplatelet agent"，Bioorganic & Medicinal Chemistry，2010年，Vol. 18, No. 11，pp. 4085-4094，DOI: 10.1016/j.bmc.2010.04.011

Also Published As

Publication number Publication date
US20230159504A1 (en) 2023-05-25
CN115697969A (zh) 2023-02-03
WO2021203028A1 (en) 2021-10-07
CA3179189A1 (en) 2021-10-07
EP4126819A1 (en) 2023-02-08
CN115697969B (zh) 2026-08-11
JP2023520397A (ja) 2023-05-17
US12662471B2 (en) 2026-06-23
AU2021246527A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
JP2023520397A (ja) アルファ１－アンチトリプシンのモジュレーター
JP7641238B2 (ja) α－１抗トリプシンモジュレーターとしての縮合三環系ピロール
JP7733670B2 (ja) アルファ１－アンチトリプシンのモジュレーター
JP7450024B2 (ja) ＦＸＩａ阻害剤及びその調製方法と医薬用途
CN115715292B (zh) α-1-抗胰蛋白酶调节剂
JP7732999B2 (ja) アルファ１－アンチトリプシンのモジュレーター
CN113164761A (zh) α-1抗胰蛋白酶的调节剂
JP2023520400A (ja) アルファ－１－アンチトリプシン欠損症（ａａｔｄ）を治療するためのアルファ－１－アンチトリプシンモジュレーターとしてのインドール誘導体
CN115776984A (zh) 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1-抗胰蛋白酶调节剂的吡咯并[2,3-f]吲唑和2,4,5,10-四氮杂三环[7.3.0.03,7]十二碳-1,3(7),5,8,11-五烯衍生物
CN120166990A (zh) α-1抗胰蛋白酶的调节剂
JP2020533328A (ja) ベンゼン縮合複素環誘導体およびその医薬組成物
TW201406736A (zh) 新穎的醯胺衍生物或其鹽
CN115109061B (zh) 三环化合物
HK40112685A (en) Glp-1r modulating compounds
HK40063845B (en) Fxia inhibitors and preparation method therefor and pharmaceutical use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250207

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250507

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251118

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251211

R150 Certificate of patent or registration of utility model

Ref document number: 7791102

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150